Menopausal Hormone Therapy and Cancer – National Cancer …

What is menopausal hormone therapy?

Menopausal hormone therapy (MHT) is a treatment that doctors may recommend to relieve common symptoms of menopause and to address long-term biological changes, such as bone loss, that result from declining levels of the natural hormones estrogen and progesterone in a womans body during and after the completion of menopause. (More information is available on the MedlinePlus Menopause page.)

MHT usually involves treatment with estrogen alone, estrogen plus progesterone, or estrogen plus progestin, which is a synthetic hormone with effects similar to those of progesterone. Women who have had a hysterectomy are generally prescribed estrogen alone. Women who have not had this surgery are prescribed estrogen plus progestin, because estrogen alone is associated with an increased risk of endometrial cancer, whereas research has suggested that estrogen plus progestin may not be.

How do the hormones used in MHT differ from the hormones produced by a womans body?

The hormones used in MHT come from a variety of plants and animals, or they can be made in a laboratory. The chemical structure of these hormones is similar, although usually not identical, to those of hormones produced by womens bodies.

The U.S. Food and Drug Administration (FDA) has approved many hormone products for use in MHT. FDA-approved products have undergone extensive testing and are produced under standardized conditions to ensure that every dosewhether in a pill, a skin patch, or a creamcontains the proper amount of the appropriate hormones. These FDA-approved products are available only with a doctors prescription. The FDA has more information about MHT in MenopauseMedicines to Help You.

Non-FDA-approved hormone products, sometimes referred to as bio-identical hormones, are widely promoted and sold without a prescription on the Internet. Claims that these products are safer or more natural than FDA-approved hormonal products are not supported by credible scientific evidence. The FDA provides more information about these products in Menopausal Hormone Therapy and Bio-identical Hormones.

Where does evidence about risks and benefits of MHT come from?

The most comprehensive evidence about risks and benefits of MHT comes from two randomized clinical trials that were sponsored by the National Institutes of Health as part of the Womens Health Initiative (WHI):

More than 27,000 healthy women who were 50 to 79 years of age at the time of enrollment took part in the two trials. Although both trials were stopped early (in 2002 and 2004, respectively) when it was determined that both types of therapy were associated with specific health risks, longer-term follow-up of the participants continues to provide new information about the health effects of MHT.

What are the benefits of menopausal hormone therapy?

Research from the WHI Estrogen-plus-Progestin study has shown that women taking combined hormone therapy had the following benefits:

However, a follow-up study found that neither benefit persisted after the study participants stopped taking combined hormone therapy medication (2).

Women taking estrogen alone experienced the following benefits:

After 10.7 years of follow-up, however, the risk of hip fractures was slightly higher in the estrogen-alone group, but the risk of breast cancer remained lower than that among women who took the placebo (4).

What are the health risks of MHT?

Before the WHI studies began, it was known that MHT with estrogen alone increased the risk of endometrial cancer in women with an intact uterus. It was for this reason that, in the WHI trials, women randomly assigned to receive hormone therapy took estrogen plus progestin if they had a uterus and estrogen alone if they didnt have one.

Research from the WHI studies has shown that MHT is associated with the following harms:

These studies also showed that both combination and estrogen-alone hormone use made mammography less effective for the early detection of breast cancer (6, 8). Women taking hormones had more repeat mammograms to check on abnormalities found in a screening mammogram and more breast biopsies to determine whether abnormalities detected in mammograms were cancer (6, 8).

The rate of death from breast cancer among those taking estrogen plus progestin was 2.6 per 10,000 women per year, compared with 1.3 per 10,000 women per year among those taking the placebo (9). The rate of death from any cause after a diagnosis of breast cancer was 5.3 per 10,000 women per year among women taking combined hormone therapy, compared with 3.4 per 10,000 women per year among those taking the placebo (9).

There were no differences in the number of cases or the number of deaths from lung cancer among women who took estrogen alone compared with those among women who took the placebo (11).

However, a subsequent analysis of the WHI trials found no strong evidence that either estrogen alone or estrogen plus progestin had any effect on the risk of colorectal cancer, tumor stage at diagnosis, or death from colorectal cancer (12).

Does hysterectomy affect the cancer risks associated with MHT?

Women who had a hysterectomy and who are prescribed MHT generally take estrogen alone.

In 2004, when the WHI Estrogen-Alone Study was stopped early, women taking estrogen alone had a 23 percent reduced risk of breast cancer compared with those who took the placebo (4). An analysis conducted after study participants had been followed for an average of 10.7 years found that women who had taken estrogen alone still had a lower risk of breast cancer than women who had taken the placebo (4).

Do the cancer risks from MHT change over time?

Women who have had a hysterectomy and who use estrogen-alone MHT have a reduced risk of breast cancer that continues for at least 5 years after they stop taking MHT (4).

Women who take combined hormone therapy have an increased risk of breast cancer that continues after they stop taking the medication (9). In the WHI study, where women took the combined hormone therapy for an average of 5.6 years, this increased risk persisted after an average follow-up period of 11 years. Breast cancers diagnosed in this group of women were larger and more likely to have spread to the lymph nodes (a sign of more advanced disease).

Studies have documented a decline in breast cancer diagnoses in the United States after the sharp reduction in the use of MHT that followed publication of the initial results of the Estrogen-plus-Progestin Study in July 2002 (13, 14). Additional factors, such as a reduction in the use of mammography, may also have contributed to this decline (15).

Is it safe for women who have had a cancer diagnosis to take MHT?

One of the roles of naturally occurring estrogen is to promote the normal growth of cells in the breast and uterus. For this reason, it is generally believed that MHT may promote further tumor growth in women who have already been diagnosed with breast cancer. However, studies of hormone use to treat menopausal symptoms in breast cancer survivors have produced conflicting results, with some showing an increased risk of breast cancer recurrence (16, 17) and others showing no increased risk of recurrence (18, 19).

What should women do if they have symptoms of menopause but are concerned about taking MHT?

Although MHT provides short-term benefits, such as relief from hot flashes and vaginal dryness, several health concerns are associated with its use. Women should discuss whether to take MHT and what alternatives may be appropriate for them with their health care provider. The FDA currently advises women to use MHT for the shortest time and at the lowest dose possible to control menopausal symptoms. The FDA publication Menopause and Hormones provides additional information about the risks and benefits of MHT use for the symptoms of menopause.

Are there alternatives for women who choose not to take menopausal hormone therapy?

Women who are concerned about the health effects that occur naturally with the decline in hormone production that occurs during menopause can make changes in their lifestyle and diet to reduce certain risks. For example, eating foods that are rich in calcium and vitamin D or taking dietary supplements containing these nutrients may help to prevent osteoporosis. FDA-approved drugs such as alendronate (Fosamax), raloxifene (Evista), and risedronate (Actonel) have been shown in randomized trials to prevent bone loss.

Medications approved by the FDA for treating depression and seizures may help to relieve menopausal symptoms such as hot flashes (20). Those that have been shown in randomized clinical trials to be effective in treating hot flashes include the following:

Some women seek relief from the symptoms of menopause with over-the-counter complementary and alternative therapies. Some of these remedies contain estrogen-like compounds derived from sources such as soy products, whole-grain cereals, oilseeds (primarily flaxseed), legumes, or the plant black cohosh. To date, however, randomized clinical trials have not shown that any of these remedies is superior to a placebo in relieving hot flashes. Trials of other herbal remedies, such as evening primrose oil, ginseng, and wild yam, have also not shown that they effectively reduce menopausal symptoms (19).

The National Institute on Aging (NIA), which is part of the National Institutes of Health (NIH), has more information about how to manage the symptoms of menopause on the Menopause AgePage.

What questions remain in this area of research?

The WHI trials were landmark studies that have transformed our understanding of the health effects of MHT. Follow-up studies have expanded and refined the original findings of these two trials. Many questions, however, remain to be answered, such as the following:

Its important to note that women who were enrolled in the WHI trials were, on average, 63 years old, although about 5,000 of them were under age 60, so the results of the study may also apply to younger women. However, women in the study were not using MHT to relieve symptoms of menopause. In addition, the WHI trials tested single-dose strengths of one estrogen-only medication (Premarin) and one estrogen-plus-progestin medication (Prempro).

NIA is sponsoring the Early Versus Late Intervention Trial With Estradiol (ELITE) to try to answer some of these remaining questions. This clinical trial is comparing the effects of estrogen in a group of women who are within 6 years of menopause and another group of women who are at least 10 years past menopause. Women are randomly assigned to take either estradiol (Estrace) or a placebo for 5 years. Women with a uterus will also use a progesterone gel or a placebo gel for the last 10 days of each month. This trial has enrolled 643 women and is expected to be completed in the summer of 2013.

NCI is supporting a range of MHT-related research, including studies aimed at understanding the genetic factors that affect womens response to MHT and the role of chronic use of female hormones in the initiation of breast cancer, as well as developing more effective nonhormonal therapies for treating hot flashes.

Where can people get more information about MHT?

The following resources provide additional information about menopausal hormones and the WHI:

Here is the original post:
Menopausal Hormone Therapy and Cancer - National Cancer ...